Ubidecarenone 120mg capsules

Statins are among the most widely prescribed drugs for treating dyslipidemia and reducing the incidence of heart disease and stroke. However, they come with a wide range of side effects, from myopathy to necrotizing rhabdomyolysis, as well as diabetes, hepatotoxicity, and sleep problems. The most common side effect of statins is statin-induced myopathy, often leading to discontinuation of statin therapy and noncompliance in many patients. This study aims to assess the effectiveness of coenzyme Q10 (CoQ10) supplementation as a treatment for patients with statin-induced myopathy. This systematic review was conducted by following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 statement. Relevant studies were identified through searches of Medline, PMC, PubMed, Science Direct, and Google Scholar. Only randomized control trials and meta-analyses of oral CoQ10 supplementation versus placebo in adults with statin-associated myalgia were included. The risk of bias was assessed using the Cochrane Risk of Bias tool (The Cochrane Collaboration, London, England, UK) and the measurement tool for the "assessment of multiple systematic reviews" (AMSTAR tool). Out of 5,000 records identified, only five were selected for this review: one meta-analysis and four randomized controlled trials. All of these studies were conducted between 2010 and 2023, involving a total of 800 patients. All randomized controlled trials showed improvement in statin-associated myopathy with CoQ10 supplementation, along with or without a reduced dosage of statins, without any notable side effects of CoQ10. Therefore, it can be deduced that CoQ10 supplementation significantly ameliorates statin-induced musculoskeletal symptoms.

Abstract licence: CC BY

PurposeTo investigate the efficacy of medical treatment options for Peyronie's disease (PD) including oral drugs, intralesional treatment and mechanical treatment compared with placebo treatment using network meta-analysis (NMA).Materials and methodsWe searched the randomized controlled trials (RCTs) of PD in PubMed, Cochrane library, and EMBASE up to October 2022. RCTs included medical treatment options: oral drugs, intralesional treatment and mechanical treatment. Studies reporting at least one of the outcome measures of interest including curvature degree, plaque size, and structured questionnaires (International Index of Erectile Function, IIEF) were included.ResultsFinally, 24 studies including 1,643 participants met our selection criteria for NMA. There was no statistically significant treatment compared to placebo of the curvature degree, plaque size, IIEF in Bayesian analysis. The SUCRA values of ranking probabilities for each treatment performance, which indicated that hyperthermia device ranked first in NMA. However, in frequentist analysis, 7 of mono treatments (coenzyme Q10 [CoQ10] 300 mg, hyperthermia device, interferon alpha 2b, pentoxifylline 400 mg, propionyl-L-carnitine 1 g, penile traction therapy [PTT], vitamin E 300 mg) and 2 of combination treatments ("PTT-extracorporeal shockwave treatment", "vitamin E 300 mg-propionyl-L-carnitine 1 g") were statistically significant for improvement of curvature degree, and 9 of mono treatments (CoQ10 300 mg, hyaluronic acid 16 mg, hyperthermia device, interferon alpha 2b, pentoxifylline 400 mg, propionyl-L-carnitine 1 g, verapamil 10 mg, vitamin E 300 mg, vitamin E 400 U) and 3 of combination treatments ("interferon alpha 2b-vitamin E 400 U", "verapamil 10 mg-antioxidants", "vitamin E 300 mg-propionyl-L-carnitine 1 g") were statistically significant in the improvement of plaque size.ConclusionsAt present, there is no clinical treatment alternatives that have been demonstrated to be effective compared to placebo. Nonetheless, as the frequentist approach has shown that a number of agents are efficacious, further research is expected to develop more effective treatment options.

Abstract licence: CC BY-NC

Background and objectiveCoenzyme Q10 is a naturally occurring antioxidant that has been suggested to improve cardiovascular health. Studies examining the effects of Q10 on blood pressure (BP) and heart rate (HR) have found inconsistent results. This meta-analysis aims to clarify the effects of Q10 administration on BP and HR in adults.MethodsA comprehensive search of online databases was conducted until February 2025 to identify relevant randomized controlled trials (RCTs). Following screening, relevant data were extracted from the eligible studies. Statistical analyses were conducted using weighted mean differences (WMD) with 95 % confidence intervals (CI). Data analysis was performed using the "meta" package in R.ResultsThe pooled analysis of 45 RCTs (48 effect sizes) showed that Q10 administration significantly reduced systolic BP (WMD: -3.44 mmHg; 95 %CI: [-5.13 to -1.55], p p = 0.23) and HR (WMD: -0.10 bpm; 95 %CI: [-2.09 - 1.89], p = 0.44). Subgroup analysis indicated that lower doses (8 weeks) resulted in greater systolic BP reductions.ConclusionThis meta-analysis indicates that CoQ10 supplementation may be an effective adjunctive therapy for reducing systolic blood pressure, especially at doses below 200 mg/day and with longer treatment durations. However, its impact on diastolic blood pressure and heart rate appears minimal. Given its favorable safety profile, CoQ10 could be considered as a supportive option in the management of hypertension, particularly for patients seeking non-pharmacological interventions or those with mild elevations in systolic BP.

Abstract licence: CC BY-NC-ND

IntroductionCoenzyme Q10 (CoQ10) is a fat-soluble vitamin-like quinone. The plasma levels of CoQ10 are reduced in patients with chronic kidney disease (CKD). CoQ10 supplementation can improve mitochondrial function and decrease oxidative stress in these patients. This systematic review will assess the renoprotective effects of CoQ10 supplementation in patients with CKD.Methods and analysisWe will include the following studies: (1) randomised-controlled trials, (2) participants with CKD and (3) participants treated with CoQ10 as an intervention. The systematic review protocol was prepared in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols. MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials and International Clinical Trials Register databases will be searched for articles without language restrictions in December 2024. The authors will be divided into two groups. Two independent authors will screen the titles and abstracts of all reports extracted via an electronic search. After the initial screening, the authors will independently review the full-text articles and perform a directed content analysis of the extracted data. For outcomes measured using continuous scales of measurement, we will adopt standardised mean differences as the effect measures. We will pool the data using the random-effects model.Ethics and disseminationNo human participants will be involved in the study. On completion of the analysis, the manuscript will be prepared for publication in a peer-reviewed journal.Prospero registration numberCRD42021241085.

Abstract licence: CC BY-NC

BackgroundSeveral meta-analyses suggest that Coenzyme Q10 (CoQ10) supplementation is associated with glycemic control; however, findings about fasting blood glucose (FBG) and haemoglobin A1c (HbA1c) remain inconsistent across studies. Accordingly, this study aimed to synthesise the results to present a firm conclusion in relation to the efficacy of CoQ10 on glycemic control.MethodsA systematic search was conducted to find meta-analyses of randomised controlled trials using PubMed, Scopus, Web of Science and the Cochrane Database of Systematic Reviews from inception to March 6, 2025. Also, the methodological quality of included studies was evaluated using the AMSTAR2 tool.ResultsIn total, eight meta-analyses were included in this umbrella systematic review and meta-analysis. Pooled analysis using standardized mean difference analysis demonstrated that CoQ10 is associated with decreased FBG. While it didn't exert any significant changes on the HbA1c, HOMA-IR, and insulin levels. In addition, the combined effect of CoQ10 using weighted mean difference analysis revealed that CoQ10 is able to decrease the FBG (5.04 mg/dL), HbA1c (0.17%), HOMA-IR (0.72), and insulin (1.32 μIU/mL) levels significantly.ConclusionThe present study suggests that CoQ10 supplementation may have a moderate beneficial effect on glycemic control in diabetic patients, though findings differ depending on analytic approach.

Abstract licence: CC BY

ObjectiveTo evaluate the effectiveness and safety of coenzyme Q10 for patients with type 2 diabetes mellitus (T2DM).MethodsData from randomized controlled trials were obtained to assess the effects of coenzyme Q10 versus placebo or western medicine on patients with T2DM. The study's registration number is CRD42018088474. The primary outcomes included glycosylated hemoglobin, fasting blood glucose, and fasting insulin.ResultThirteen trials involving 765 patients were included. Compared with the control group, coenzyme Q10 may decrease the HbA1c (WMD -0.29; 95% CI -0.54, -0.03; P = 0.03) and the fasting blood glucose (WMD -11.21; 95% CI -18.99, -3.43; P = 0.005). For fasting insulin, there is also not strong evidence that confirms which one is better because there was no statistical difference (WMD -0.48; 95% CI -2.54, 1.57; P = 0.65).ConclusionBased on current evidence, coenzyme Q10 may assist glycemic control, decrease TG, and improve HDL-C in patients with T2DM.

Abstract licence: CC BY

IntroductionCoenzyme Q10 (CoQ10) is a fat-soluble vitamin-like quinone that exerts antioxidative functions and is also an important factor in mitochondrial metabolism. Plasma concentrations of CoQ10 are depressed in patients with chronic kidney disease (CKD). CoQ10 supplement can reduce adverse cardiovascular events, improve mitochondrial function and decrease oxidative stress in patients with non-dialysis CKD and dialysis CKD. We performed this study as a systematic review to comprehensively assess the effect of CoQ10 supplement on patients with CKD.Methods and analysisThe present systematic review protocol is reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analysis Protocols guidelines. The MEDLINE, EMBASE and Cochrane library databases will be searched without language restrictions in December 2018. Two reviewers will independently screen the references in two stages: screening of the title/abstract and then of the full-text, to identify references meeting the inclusion criteria. A descriptive overview and tabular and/or graphical summaries will be generated, and directed content analysis will be carried out on the extracted data.Ethics and disseminationThis systematic review will evaluate the efficacy and safety of CoQ10 in patients with CKD. Ethical approval is not required for this study. The results of this systematic review will be presented in relevant conferences and published in a peer-review journal.Prospero registration numberCRD42019120201.

Abstract licence: CC BY-NC